CN110719787B - 用于治疗自身免疫病的rna - Google Patents

用于治疗自身免疫病的rna Download PDF

Info

Publication number
CN110719787B
CN110719787B CN201880024391.7A CN201880024391A CN110719787B CN 110719787 B CN110719787 B CN 110719787B CN 201880024391 A CN201880024391 A CN 201880024391A CN 110719787 B CN110719787 B CN 110719787B
Authority
CN
China
Prior art keywords
cells
immunogenic
mrna
rna
cell
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201880024391.7A
Other languages
English (en)
Chinese (zh)
Other versions
CN110719787A (zh
Inventor
乌尔·沙欣
塞巴斯蒂安·克赖特尔
克里斯蒂纳·克林克
尤塔·佩茨申卡
莱娜·马伦·克兰斯
穆斯塔法·迪肯
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Translationale Onkologie An Der Universitatsmedizin Der Johannes Gutenberg-Univers
Debiotech SA
Original Assignee
Translationale Onkologie An Der Universitatsmedizin Der Johannes Gutenberg-Univers
Debiotech SA
Biontech RNA Pharmaceuticals GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Translationale Onkologie An Der Universitatsmedizin Der Johannes Gutenberg-Univers, Debiotech SA, Biontech RNA Pharmaceuticals GmbH filed Critical Translationale Onkologie An Der Universitatsmedizin Der Johannes Gutenberg-Univers
Priority to CN202410206779.6A priority Critical patent/CN118161602A/zh
Publication of CN110719787A publication Critical patent/CN110719787A/zh
Application granted granted Critical
Publication of CN110719787B publication Critical patent/CN110719787B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0008—Antigens related to auto-immune diseases; Preparations to induce self-tolerance
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/0008—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition
    • A61K48/0025—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition wherein the non-active part clearly interacts with the delivered nucleic acid
    • A61K48/0033—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition wherein the non-active part clearly interacts with the delivered nucleic acid the non-active part being non-polymeric
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers
    • A61K9/1272—Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers comprising non-phosphatidyl surfactants as bilayer-forming substances, e.g. cationic lipids or non-phosphatidyl liposomes coated or grafted with polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
    • C12N15/1003—Extracting or separating nucleic acids from biological samples, e.g. pure separation or isolation methods; Conditions, buffers or apparatuses therefor
    • C12N15/1006—Extracting or separating nucleic acids from biological samples, e.g. pure separation or isolation methods; Conditions, buffers or apparatuses therefor by means of a solid support carrier, e.g. particles, polymers
    • C12N15/101—Extracting or separating nucleic acids from biological samples, e.g. pure separation or isolation methods; Conditions, buffers or apparatuses therefor by means of a solid support carrier, e.g. particles, polymers by chromatography, e.g. electrophoresis, ion-exchange, reverse phase
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/117—Nucleic acids having immunomodulatory properties, e.g. containing CpG-motifs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6018—Lipids, e.g. in lipopeptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/33—Chemical structure of the base
    • C12N2310/335—Modified T or U

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Mycology (AREA)
  • Rheumatology (AREA)
  • Transplantation (AREA)
  • Analytical Chemistry (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Dispersion Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
CN201880024391.7A 2017-04-11 2018-04-10 用于治疗自身免疫病的rna Active CN110719787B (zh)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN202410206779.6A CN118161602A (zh) 2017-04-11 2018-04-10 用于治疗自身免疫病的rna

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EPPCT/EP2017/058651 2017-04-11
PCT/EP2017/058651 WO2018188730A1 (en) 2017-04-11 2017-04-11 Rna for treatment of autoimmune diseases
PCT/EP2018/059188 WO2018189193A1 (en) 2017-04-11 2018-04-10 Rna for treatment of autoimmune diseases

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CN202410206779.6A Division CN118161602A (zh) 2017-04-11 2018-04-10 用于治疗自身免疫病的rna

Publications (2)

Publication Number Publication Date
CN110719787A CN110719787A (zh) 2020-01-21
CN110719787B true CN110719787B (zh) 2024-03-15

Family

ID=58632945

Family Applications (2)

Application Number Title Priority Date Filing Date
CN201880024391.7A Active CN110719787B (zh) 2017-04-11 2018-04-10 用于治疗自身免疫病的rna
CN202410206779.6A Pending CN118161602A (zh) 2017-04-11 2018-04-10 用于治疗自身免疫病的rna

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN202410206779.6A Pending CN118161602A (zh) 2017-04-11 2018-04-10 用于治疗自身免疫病的rna

Country Status (23)

Country Link
US (2) US11701413B2 (https=)
EP (2) EP3609529B1 (https=)
JP (3) JP7078641B2 (https=)
KR (2) KR20240042138A (https=)
CN (2) CN110719787B (https=)
AU (1) AU2018253352B2 (https=)
BR (1) BR112019020667A8 (https=)
CA (1) CA3059505A1 (https=)
CY (1) CY1124767T1 (https=)
DK (1) DK3609529T3 (https=)
ES (1) ES2893451T3 (https=)
HR (1) HRP20211559T1 (https=)
HU (1) HUE056871T2 (https=)
IL (2) IL269793B (https=)
LT (1) LT3609529T (https=)
MX (1) MX2019012144A (https=)
PL (1) PL3609529T3 (https=)
PT (1) PT3609529T (https=)
RS (1) RS62582B1 (https=)
SG (2) SG11201909520VA (https=)
SI (1) SI3609529T1 (https=)
SM (1) SMT202100572T1 (https=)
WO (2) WO2018188730A1 (https=)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018188730A1 (en) * 2017-04-11 2018-10-18 Biontech Rna Pharmaceuticals Gmbh Rna for treatment of autoimmune diseases
CA3119449A1 (en) * 2018-11-12 2020-05-22 Translate Bio, Inc. Methods for inducing immune tolerance
IL297419B2 (en) * 2020-04-22 2025-02-01 BioNTech SE Coronavirus vaccine
CN116710115A (zh) 2020-11-20 2023-09-05 思维疗法股份有限公司 用于优化的肽疫苗的组合物和方法
US11058751B1 (en) 2020-11-20 2021-07-13 Think Therapeutics, Inc. Compositions for optimized RAS peptide vaccines
US11161892B1 (en) 2020-12-07 2021-11-02 Think Therapeutics, Inc. Method of compact peptide vaccines using residue optimization
US11421015B2 (en) 2020-12-07 2022-08-23 Think Therapeutics, Inc. Method of compact peptide vaccines using residue optimization
CN115232825B (zh) * 2021-04-22 2023-09-26 中国人民解放军军事科学院军事医学研究院 一种基于1083骨架的新冠病毒疫苗
US11464842B1 (en) 2021-04-28 2022-10-11 Think Therapeutics, Inc. Compositions and method for optimized peptide vaccines using residue optimization
CN117750971A (zh) 2021-05-26 2024-03-22 易姆赛斯股份公司 治疗或预防自身免疫病的方法
AR126654A1 (es) 2021-06-29 2023-11-01 Imcyse Sa Péptidos y métodos para el tratamiento de neuromielitis óptica
CN113336862B (zh) * 2021-07-05 2022-03-01 广东省科学院动物研究所 一种抗多发性硬化的重组蛋白及其制备方法和用途
WO2023030635A1 (en) * 2021-09-02 2023-03-09 BioNTech SE Potency assay for therapeutic potential of coding nucleic acid
CN118369335A (zh) * 2022-01-06 2024-07-19 上海吉量医药工程有限公司 N1位修饰假尿嘧啶核苷及其在mRNA合成中的应用

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1703505A (zh) * 2002-09-16 2005-11-30 沃尔特及伊莱萨霍尔医学研究院 一种治疗自身免疫病的方法
WO2007024708A2 (en) * 2005-08-23 2007-03-01 The Trustees Of The University Of Pennsylvania Rna containing modified nucleosides and methods of use thereof
CN102947450A (zh) * 2009-12-07 2013-02-27 宾夕法尼亚州大学信托人 用于重编程细胞的包含纯化的经修饰的rna的rna制剂
WO2013102203A1 (en) * 2011-12-30 2013-07-04 Cellscript, Inc. MAKING AND USING IN VITRO-SYNTHESIZED ssRNA FOR INTRODUCING INTO MAMMALIAN CELLS TO INDUCE A BIOLOGICAL OR BIOCHEMICAL EFFECT
WO2014160243A1 (en) * 2013-03-14 2014-10-02 The Trustees Of The University Of Pennsylvania Purification and purity assessment of rna molecules synthesized with modified nucleosides
WO2016176330A1 (en) * 2015-04-27 2016-11-03 The Trustees Of The University Of Pennsylvania Nucleoside-modified rna for inducing an adaptive immune response
WO2017182524A1 (en) * 2016-04-22 2017-10-26 Biontech Rna Pharmaceuticals Gmbh Methods for providing single-stranded rna

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7030098B2 (en) * 1999-03-12 2006-04-18 The Board Of Trustees Of The Leland Stanford Junior University DNA vaccination for treatment of autoimmune disease
US9012219B2 (en) * 2005-08-23 2015-04-21 The Trustees Of The University Of Pennsylvania RNA preparations comprising purified modified RNA for reprogramming cells
WO2009030254A1 (en) * 2007-09-04 2009-03-12 Curevac Gmbh Complexes of rna and cationic peptides for transfection and for immunostimulation
EP2050814A1 (en) 2007-10-17 2009-04-22 Txcell Compositions for treating multiple sclerosis
WO2012154933A1 (en) * 2011-05-10 2012-11-15 The Brigham And Women's Hospital, Inc. Detecting inclusion body myositis
CN103998055B (zh) * 2011-09-30 2017-10-24 北京艾棣维欣生物技术有限公司 预防和治疗自身免疫性疾病的联合促进剂、抗原和dna疫苗
WO2013120498A1 (en) * 2012-02-15 2013-08-22 Curevac Gmbh Nucleic acid comprising or coding for a histone stem-loop and a poly(a) sequence or a polyadenylation signal for increasing the expression of an encoded allergenic antigen or an autoimmune self-antigen
CN106395552B (zh) 2015-08-03 2020-03-17 奥的斯电梯公司 无绳电梯系统导轨组件
US10808242B2 (en) * 2015-08-28 2020-10-20 Biontech Rna Pharmaceuticals Gmbh Method for reducing immunogenicity of RNA
WO2018188730A1 (en) * 2017-04-11 2018-10-18 Biontech Rna Pharmaceuticals Gmbh Rna for treatment of autoimmune diseases

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1703505A (zh) * 2002-09-16 2005-11-30 沃尔特及伊莱萨霍尔医学研究院 一种治疗自身免疫病的方法
WO2007024708A2 (en) * 2005-08-23 2007-03-01 The Trustees Of The University Of Pennsylvania Rna containing modified nucleosides and methods of use thereof
CN102947450A (zh) * 2009-12-07 2013-02-27 宾夕法尼亚州大学信托人 用于重编程细胞的包含纯化的经修饰的rna的rna制剂
WO2013102203A1 (en) * 2011-12-30 2013-07-04 Cellscript, Inc. MAKING AND USING IN VITRO-SYNTHESIZED ssRNA FOR INTRODUCING INTO MAMMALIAN CELLS TO INDUCE A BIOLOGICAL OR BIOCHEMICAL EFFECT
WO2014160243A1 (en) * 2013-03-14 2014-10-02 The Trustees Of The University Of Pennsylvania Purification and purity assessment of rna molecules synthesized with modified nucleosides
WO2016176330A1 (en) * 2015-04-27 2016-11-03 The Trustees Of The University Of Pennsylvania Nucleoside-modified rna for inducing an adaptive immune response
WO2017182524A1 (en) * 2016-04-22 2017-10-26 Biontech Rna Pharmaceuticals Gmbh Methods for providing single-stranded rna

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
Generating the optimal mRNA for therapy:HPLC purification eliminates immune activation and improves translation of nucleoside-modified，protein-encoding mRNA;Katalin Kariko等;Nucleic Acids Research;第39卷(第21期);第e142页摘要、"mRNA synthesis"和"HPLC purification of RNA"部分以及图3-5 *
Rapid isolation of mycoviral double-stranded RNA from Botrytis cinerea and Saccharomyces cerevisiae;Antonio Castillo等;Virology Journal;第38卷;第38页 *
用于肿瘤治疗的小分子干扰RNA非病毒载体研究进展;王欢等;药学实践杂志(第8期);第498-501页 *

Also Published As

Publication number Publication date
US20200061166A1 (en) 2020-02-27
DK3609529T3 (da) 2021-10-11
CY1124767T1 (el) 2022-11-25
WO2018188730A1 (en) 2018-10-18
US20230330198A1 (en) 2023-10-19
LT3609529T (lt) 2021-10-25
KR102824942B1 (ko) 2025-06-25
IL269793A (en) 2019-11-28
SI3609529T1 (sl) 2021-11-30
MX2019012144A (es) 2019-11-21
IL290980A (en) 2022-05-01
EP3981424A1 (en) 2022-04-13
CN118161602A (zh) 2024-06-11
RU2019135808A3 (https=) 2021-08-10
SMT202100572T1 (it) 2021-11-12
HRP20211559T1 (hr) 2022-01-21
SG11201909520VA (en) 2019-11-28
KR20240042138A (ko) 2024-04-01
EP3609529B1 (en) 2021-09-08
CN110719787A (zh) 2020-01-21
JP2020516658A (ja) 2020-06-11
AU2018253352B2 (en) 2025-04-10
IL269793B (en) 2022-04-01
PL3609529T3 (pl) 2021-12-13
KR20190134765A (ko) 2019-12-04
US11701413B2 (en) 2023-07-18
RS62582B1 (sr) 2021-12-31
JP7444924B2 (ja) 2024-03-06
PT3609529T (pt) 2021-10-14
RU2019135808A (ru) 2021-05-11
CA3059505A1 (en) 2018-10-18
HUE056871T2 (hu) 2022-04-28
EP3609529A1 (en) 2020-02-19
ES2893451T3 (es) 2022-02-09
JP2022110127A (ja) 2022-07-28
BR112019020667A8 (pt) 2022-08-16
WO2018189193A1 (en) 2018-10-18
JP2024059794A (ja) 2024-05-01
BR112019020667A2 (pt) 2020-05-05
SG10202111163VA (en) 2021-11-29
JP7078641B2 (ja) 2022-05-31
AU2018253352A1 (en) 2019-10-17

Similar Documents

Publication Publication Date Title
CN110719787B (zh) 用于治疗自身免疫病的rna
TW202023629A (zh) 用於調節單核球及巨噬細胞發炎表型之組合物及方法以及其免疫療法用途
US12168051B2 (en) Methods and compositions for stimulating immune response
US20240182543A1 (en) Engineered chimeric fusion protein compositions and methods of use thereof
TW202245808A (zh) 用於治療癌症之治療性ｒｎａ
AU2022362640A1 (en) Therapeutic rna for lung cancer
JP2024522179A (ja) 免疫エフェクタ細胞の活性化および標的化のための薬剤および方法
US20250277223A1 (en) Methods of treating or preventing autoimmune diseases
RU2790447C2 (ru) Рнк для лечения аутоиммунных заболеваний
HK40070905A (en) Rna for treatment of autoimmune diseases
HK40017292B (en) Rna for treatment of autoimmune diseases
HK40017292A (en) Rna for treatment of autoimmune diseases
HK40099663A (zh) 用於治疗癌症的治疗性rna

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
TA01 Transfer of patent application right
TA01 Transfer of patent application right

Effective date of registration: 20220126

Address after: Mainz, Germany

Applicant after: DEBIOTECH S.A.

Applicant after: Translationale Onkologie an der Universitatsmedizin der Johannes Gutenberg-Univers

Address before: Mainz, Germany

Applicant before: BIONTECH RNA PHARMACEUTICALS GmbH

Applicant before: Translationale Onkologie an der Universitatsmedizin der Johannes Gutenberg-Univers

GR01 Patent grant
GR01 Patent grant
TG01 Patent term adjustment

Free format text: NEW EXPIRY DATE: 20380904

TG01 Patent term adjustment